Multiple treatment failures with evolving tumor biology requiring constant adaptation.
Our Impact
Our team matched treatments to shifting biomarkers, including inhibitors for DNA repair mutations, combination therapy for PI3K pathway mutations, and a CDK4/6 inhibitor for hormone sensitivity.
The Outcome
She achieved sequential partial responses across more than five therapies over multiple years, maintaining control by staying ahead of disease evolution.
